参考文献

1.Benevolo G，Stacchini A，Spina M，et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood，2012，120（16）：3222-8.doi：10.1182/blood-2012-04-423095.

2.Swerdlow SH，Campo E，Pileri SA，et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood，2016，127（20）：2375-90.doi：10.1182/blood-2016-01-643569.

3.Lenz G，Wright GW，Emre NC，et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways［J］.Proc Natl Acad Sci U S A，2008，105（36）：13520-5.doi：10.1073/pnas.0804295105.

4.Scott DW，Wright GW，Williams PM，et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood，2014，123（8）：1214-7.doi：10.1182/blood-2013-11-536433.

5.Wright G，Tan B，Rosenwald A，et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A，2003，100（17）：9991-6.doi：10.1073/pnas.1732008100.

6.Savage KJ，Johnson NA，Ben-Neriah S，et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood，2009，114（17）：3533-7.doi：10.1182/blood-2009-05-220095.

7.Barrans S，Crouch S，Smith A，et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2010，28（20）：3360-5.doi：10.1200/jco.2009.26.3947.

8.Lin P，Dickason TJ，Fayad LE，et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma，unclassifiable，with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer，2012，118（6）：1566-73.doi：10.1002/cncr.26433.

9.Green TM，Young KH，Visco C，et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2012，30（28）：3460-7.doi：10.1200/jco.2011.41.4342.

10.Johnson NA，Slack GW，Savage KJ，et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide，doxorubicin，vincristine，and prednisone. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2012，30（28）：3452-9.doi：10.1200/jco.2011.41.0985.

11.Horn H，Ziepert M，Becher C，et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood，2013，121（12）：2253-63.doi：10.1182/blood-2012-06-435842.

12.Xue K，Gu JJ，Zhang Q，et al. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma：Results from a randomized prospective clinical trial. Oncotarget，2016，7（22）：32519-31.doi：10.18632/oncotarget.8685.

13.Cai QC，Gao Y，Wang XX，et al. Long-term results of the R-CEOP90 in the treatment of young patients with chemotherapy-naive diffuse large B cell lymphoma：a phase Ⅱ study. Leukemia & lymphoma，2014，55（10）：2387-8.doi：10.3109/10428194.2013.876632.

14.Held G，Murawski N，Ziepert M，et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2014，32（11）：1112-8.doi：10.1200/jco.2013.51.4505.

15.Pfreundschuh M，Kuhnt E，Trumper L，et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diff use large-B-cell lymphoma：6-year results of an open-label randomised study of the MabThera International Trial（MInT）Group. The Lancet Oncology，2011，12（11）：1013-22.doi：10.1016/s1470-2045（11）70235-2.

16.Stephens DM，Li H，LeBlanc ML，et al. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma：Final and Long-Term Analysis of Southwest Oncology Group Study S8736［J］.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2016，34（25）：2997-3004.doi：10.1200/JCO.2015.65.4582.

17.Vargo JA，Gill BS，Balasubramani GK，et al. Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma：Do We Still Need Consolidative Radiotherapy ？［J］.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2015.doi：10.1200/JCO.2015.61.7654.

18.Howlett C，Snedecor S，Landsburg D，et al. Front-line dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas：a systematic review and meta-analysis. Br J Hacmatol，2015，170（4）：504-514.

19.Dunleavy K，Pittaluga S，Maeda LS，et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. The New England journal of medicine，2013，368（15）：1408-16.doi：10.1056/NEJMoa1214561.

20.Morris PG，Correa DD，Yahalom J，et al. Rituximab，methotrexate，procarbazine，and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma：final results and long-term outcome. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2013，31（31）：3971-9.doi：10.1200/JCO.2013.50.4910.

21.Thiel E，Korfel A，Martus P，et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma（G-PCNSL-SG-1）：a phase 3，randomised，non-inferiority trial. The Lancet Oncology，2010，11（11）：1036-47.doi：10.1016/S1470-2045（10）70229-70231.

22.Schmitz N，Zeynalova S，Nickelsen M，et al. CNS International Prognostic Index：A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2016，34（26）：3150-6.doi：10.1200/jco.2015.65.6520.

23.Hagberg H，Gisselbrecht C；CORAL study group. Randomised phase Ⅲ study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma（DLBCL）followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not：an update of the CORAL study. Ann Oncol.2006 May；17 Suppl 4：iv31-2.

24.Shen QD，Zhu HY，Wang L，et al. Gemcitabine-oxaliplatin plus rituximab（R-GemOx）as first-line treatment in elderly patients with diffuse large B-cell lymphoma：a single-arm，open-label，phase 2 trial. Lancet Haematol.2018 Jun；5（6）：e261-e269.doi：10.1016/S2352-3026（18）30054-1.

25.Crump M，Kuruvilla J，Couban S，et al. Randomized comparison of gemcitabine，dexamethasone，and cisplatin versus dexamethasone，cytarabine，and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas：NCIC-CTG LY.12.J Clin Oncol.2014 Nov 1；32（31）：3490-6.doi：10.1200/JCO.2013.53.9593.

26.Rodriguez MA，Cabanillas FC，Velasquez W，et al. Results of a salvage treatment program for relapsing lymphoma：MINE consolidated with ESHAP. J Clin Oncol.1995 Jul；13（7）：1734-1741.

27.Wiernik PH，Lossos IS，Tuscano JM，et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol.2008 Oct 20；26（30）：4952-7.doi：10.1200/JCO.2007.15.3429.

28.Witzig TE，Vose JM，Zinzani PL，et al. An international phaseⅡtrial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol.2011 Jul；22（7）：1622-7.doi：10.1093/annonc/mdq626.

29.Wang M，Fowler N，Wagner-Bartak N，et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell，follicular and transformed lymphoma：a phase Ⅱ clinical trial. Leukemia.2013 Sep；27（9）：1902-9.doi：10.1038/leu.2013.95.